Posted by Michael Wonder on 03 Mar 2023
Bayer submits aflibercept 8 mg for marketing authorisation in Japan
1 March 2023 - Submission to the MHLW in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema is based on positive results of Phase 3 clinical trials, PULSAR and PHOTON.
Bayer has submitted an application to the Japanese Ministry of Health, Labor, and Welfare seeking approval of aflibercept 8 mg for the treatment of two major retinal diseases, neovascular (wet) age-related macular degeneration and diabetic macular oedema.
